ArticleHistopathology2026
To VAE or not to VAE: outcomes of radial scars/complex sclerosing lesions and papillary lesions without atypia in the King's College Hospital breast service (2017-2023).
Article in Histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Management of high-risk (B3) breast lesions in symptomatic practice: evidence review and practical recommendations for multidisciplinary care.Virchows Archiv : an international journal of pathology · 2026Review
- Management of Radial Scars and Complex Sclerosing Lesions of the Breast: To Excise or Not to Excise?World journal of surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsSince there is currently limited data regarding the risk of malignancy that radial scars/complex sclerosing lesions (RS/CSL) or papillary lesions without atypia carry, we reviewed all such cases treated at King's College Hospital between January 2017 and June 2023 to determine the upgrade rates following immediate excision and longer follow-up. METHODS AND
resultsPatients were identified using electronic database searches. An 'upgrade' was defined as the presence of ductal carcinoma in situ (DCIS) or invasive breast carcinoma (IBC) on excision at the biopsy site. One hundred and two patients had RS/CSL (85% screen-detected; 15% symptomatic). Only one (1%) of the 90 patients who underwent excision was upgraded to DCIS; none to IBC. On longer follow-up, four patients (4%) developed ipsilateral DCIS/IBC, while one patient developed contralateral DCIS with microinvasion. Two hundred and twenty-six patients had papillary lesions without atypia (42% screen-detected; 58% symptomatic). Eight (4%) of the 179 patients who underwent excision were upgraded to DCIS; none to IBC. On longer follow-up, one patient developed ipsilateral DCIS; another patient developed contralateral IBC. For both lesions, radiological size was not significantly associated with atypia/upgrade (P > 0.05; Mann-Whitney U-test).
conclusionSince RS/CSL without atypia carry a low upgrade risk (1%), these patients could avoid excision and be followed up with mammographic surveillance. However, further data are needed for this change in practice to be considered. Papillary lesions without atypia appear to be more heterogeneous in behaviour, carrying an upgrade risk of 4%. Current treatment guidelines should not change until we better understand the biology of these lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.